Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial

Trial Profile

Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Donepezil; Galantamine
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Jun 2008 Status changed from recruiting to discontinued.
    • 02 Feb 2007 Status changed from planning to recruiting.
    • 29 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top